How Analysts Rated Prothena Corporation plc (NASDAQ:PRTA) Last Week?

September 14, 2018 - By Rachel Eickhoff

Prothena Corporation plc (NASDAQ:PRTA) LogoInvestors sentiment decreased to 0.86 in Q2 2018. Its down 0.03, from 0.89 in 2018Q1. It turned negative, as 31 investors sold Prothena Corporation plc shares while 28 reduced holdings. 20 funds opened positions while 31 raised stakes. 29.12 million shares or 2.41% less from 29.85 million shares in 2018Q1 were reported.
Hall Laurie J Trustee has 0% invested in Prothena Corporation plc (NASDAQ:PRTA) for 90 shares. Carroll Financial holds 0% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 1 shares. Natl Bank Of Montreal Can reported 20,549 shares stake. Citadel Lc reported 0% in Prothena Corporation plc (NASDAQ:PRTA). Moreover, Federated Inc Pa has 0% invested in Prothena Corporation plc (NASDAQ:PRTA). Georgia-based Invesco has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Vanguard Grp Incorporated holds 0% or 1.07M shares in its portfolio. Camarda Financial Advisors Limited Liability Corporation reported 12 shares or 0% of all its holdings. Commercial Bank Of Ny Mellon Corporation stated it has 0% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). New York State Common Retirement Fund accumulated 41,600 shares. Hap Trading Lc holds 0.09% or 128,930 shares in its portfolio. Bnp Paribas Arbitrage Sa invested in 4,007 shares. Royal Commercial Bank Of Canada reported 0% stake. Credit Suisse Ag has 40,778 shares. Voya Investment Mgmt Llc accumulated 16,988 shares or 0% of the stock.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

Among 9 analysts covering Prothena Corp (NASDAQ:PRTA), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Prothena Corp had 14 analyst reports since March 20, 2018 according to SRatingsIntel. Deutsche Bank maintained Prothena Corporation plc (NASDAQ:PRTA) on Tuesday, April 24 with “Buy” rating. The rating was downgraded by Evercore on Monday, April 23 to “In-Line”. The stock of Prothena Corporation plc (NASDAQ:PRTA) has “Hold” rating given on Monday, April 23 by Barclays Capital. Cantor Fitzgerald maintained the shares of PRTA in report on Friday, June 15 with “Overweight” rating. The company was maintained on Thursday, April 5 by Barclays Capital. The rating was maintained by Nomura with “Buy” on Tuesday, April 24. The rating was downgraded by BTIG Research on Tuesday, April 24 to “Neutral”. Barclays Capital downgraded the shares of PRTA in report on Monday, May 21 to “Sell” rating. Cantor Fitzgerald maintained Prothena Corporation plc (NASDAQ:PRTA) rating on Tuesday, March 20. Cantor Fitzgerald has “Buy” rating and $69.0 target. Cantor Fitzgerald maintained Prothena Corporation plc (NASDAQ:PRTA) on Tuesday, April 24 with “Overweight” rating. Below is a list of Prothena Corporation plc (NASDAQ:PRTA) latest ratings and price target changes.

15/06/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $14 New Target: $18 Maintain
21/05/2018 Broker: Barclays Capital Rating: Sell New Target: $12.0000 Downgrade
24/04/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $87 New Target: $19 Maintain
24/04/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $78 New Target: $16 Maintain
24/04/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $77 Downgrade
24/04/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $14 Maintain
23/04/2018 Broker: Oppenheimer Rating: Hold Downgrade
23/04/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
23/04/2018 Broker: Barclays Capital Rating: Hold Downgrade
23/04/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Old Target: $100 Downgrade

The stock decreased 2.61% or $0.36 during the last trading session, reaching $13.44. About 163,116 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has declined 77.78% since September 14, 2017 and is downtrending. It has underperformed by 93.40% the S&P500.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $535.41 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

More recent Prothena Corporation plc (NASDAQ:PRTA) news were published by: Seekingalpha.com which released: “The Battle For Best-In-Class In ATTR Has Begun” on August 16, 2018. Also Nasdaq.com published the news titled: “Investor Expectations to Drive Momentum within Rapid7, 1-800 FLOWERS.COM, SMART Global, Prothena Corporation …” on August 20, 2018. Digitaljournal.com‘s news article titled: “September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action …” with publication date: September 13, 2018 was also an interesting one.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.